Women’s Health Update

With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.

There are gaps in resources available to care for patients with mycoplasma genitalium (MGen). Since access to testing and to resistance testing are critical to be able to properly care for women suspected of having MGen, Dr. Mimi Secor talks with Dr. Maria Trent from Johns Hopkins School of Medicine about how clinicians can overcome common diagnostic and treatment challenges and shares guidelines updates from the CDC.

Dr. Mimi Secor is joined by Dr. Maria Trent to discuss mycoplasma genitalium (MGen), how we can better understand this infection and help reduce our patients' risk of it.

Dr. Mimi Secor is joined by Dr. Maria Trent, Chief of the Division of Adolescent and Young Adult Medicine at Johns Hopkins School of Medicine, to discuss diagnosing and treating antibiotic resistant MGen.

Diagnosing vaginal infections early and accurately is key, but are current testing methods for vaginal infections facilitating early diagnosis? Joining Dr. Charles Turck to help answer this question are Drs. Christina Muzny and Paul Nirjesky, who share their multidisciplinary viewpoints on vaginal infections and diagnostic practices in women’s health.

Dr. Barbara Van Der Pol, a Professor of Medicine in Infectious Diseases at The University of Alabama at Birmingham and Scientist at the Center for Women’s Reproductive Health briefly discusses how rapid testing could impact the treatment landscape for sexually transmitted infections.

The number one cause of death for women in the United States is cardiovascular disease. Luckily, providers can help identify their patients’ risk and educate them on the preventive measures available that can help mitigate their risk. Listen in as Dr. Jay Wohlgemuth speaks with Dr. Felice Gersh about diagnostic tests available for women today.

Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.